Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)
Autor: | H.J. Jansen, Helena M. de Wit, Cees J. Tack, Bastiaan E. de Galan, Wim J C de Grauw, Gerald Vervoort |
---|---|
Rok vydání: | 2014 |
Předmět: |
Blood Glucose
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] Type 2 diabetes Weight Gain Gastroenterology law.invention Randomized controlled trial Glucagon-Like Peptide 1 law Internal medicine Diabetes mellitus Internal Medicine Clinical endpoint medicine Humans Hypoglycemic Agents Insulin Aged Intention-to-treat analysis business.industry Liraglutide Other Research Radboud Institute for Health Sciences [Radboudumc 0] Metabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6] Middle Aged medicine.disease Endocrinology Diabetes Mellitus Type 2 Female medicine.symptom business Weight gain medicine.drug |
Zdroj: | Diabetologia, 57, 1812-9 Diabetologia, 57, 9, pp. 1812-9 |
ISSN: | 1432-0428 0012-186X |
DOI: | 10.1007/s00125-014-3302-0 |
Popis: | Item does not contain fulltext AIMS/HYPOTHESIS: The best treatment strategy for a patient with type 2 diabetes who shows pronounced weight gain after the introduction of insulin treatment is unclear. We determined whether addition of a glucagon-like peptide-1 (GLP-1) analogue could reverse pronounced insulin-associated weight gain while maintaining glycaemic control, and compared this with the most practised strategy, continuation and intensification of standard insulin therapy. METHODS: In a 26-week, randomised controlled trial (ELEGANT), conducted in the outpatient departments of one academic and one large non-academic teaching hospital in the Netherlands, adult patients with type 2 diabetes with >/= 4% weight gain during short-term ( |
Databáze: | OpenAIRE |
Externí odkaz: |